onQuest Group

OnQuest is a South Korean biotechnology company focused on developing next-generation cancer immunotherapies by modulating the tumor microenvironment (TME). The company's lead candidate, OQ-001, is a potent and selective small molecule inhibitor targeting the TGF-beta signaling pathway to overcome resistance to existing immune checkpoint inhibitors. OnQuest's pipeline also includes programs targeting tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) to restore anti-tumor immune responses. Founded by experts in oncology and drug development, the company aims to provide novel solutions for patients with refractory solid tumors through targeted TME modulation.